
    
      Phase 3 randomized, double-blind, placebo-controlled, study to evaluate the efficacy and
      safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and
      prednisone (R-CHOP) as compared with placebo plus R-CHOP in subjects â‰¤65 years of age with
      previously untreated non-germinal center diffuse large B-cell lymphoma (activated B-cell
      (ABC) and unclassified).
    
  